Skip to main content
Journal of Investigative Medicine High Impact Case Reports logoLink to Journal of Investigative Medicine High Impact Case Reports
. 2026 Apr 3;14:23247096261440338. doi: 10.1177/23247096261440338

Expanding the Phenotypic Spectrum of SLC1A4-Related Spastic Tetraplegia: A Case With Novel Multisystem Features

Ramzi H Mujahed 1,2, Leyana Alawawdeh 1, Baraa Nassar 1, Ranya Abu Khalaf 1, Adam Hafiz Qabaha 1, Taha Z Makhlouf 1,✉
PMCID: PMC13051137  PMID: 41934118

Abstract

Spastic tetraplegia, thin corpus callosum, and progressive microcephaly (SPATCCM) is a rare autosomal recessive neurodevelopmental disorder caused by pathogenic variants in the SLC1A4 gene. 24 cases have been reported worldwide. We describe a 30-month-old boy born to consanguineous parents, presenting with global developmental delay, seizures, progressive microcephaly, spastic tetraplegia, feeding difficulties, and recurrent infections. Genetic testing confirmed a homozygous pathogenic variant in SLC1A4 (p.Arg457Trp). Notably, our patient exhibited novel systemic phenotypic features, including grade 2 finger clubbing, recurrent infections, bilateral hernias, meatal stenosis, and dysmorphic features (high-arched palate, low-set ears, pectus carinatum). Brain MRI demonstrated a diffusely thin corpus callosum, a typical finding consistent with the classic SPATCCM phenotype. These previously unreported systemic features broaden the recognized phenotypic spectrum and underscore the need for genetic testing in suspected cases.

Keywords: SLC1A4 gene, SPATCCM, progressive microcephaly, spastic tetraplegia, phenotypic expansion, neurodevelopmental disorder

Introduction

The SLC1A4 gene encodes the alanine–serine–cysteine transporter 1 (ASCT1), a sodium-dependent neutral amino acid transporter that mediates the transfer of amino acids, particularly L-serine, from astrocytes to neurons. This process is essential for normal brain development and neuronal function. 1 Pathogenic variants in SLC1A4 cause a very rare autosomal recessive neurodevelopmental disorder known as spastic tetraplegia, thin corpus callosum, and progressive microcephaly (SPATCCM). 2 SPATCCM is characterized by early-onset spastic tetraplegia, progressive microcephaly, thinning of the corpus callosum, and severe global developmental delay beginning in infancy. The disorder was first described simultaneously in 2015 by Srour et al, who reported two affected siblings from an Ashkenazi Jewish consanguineous family, 3 and Damseh et al, who described 11 patients (10 Ashkenazi Jewish and 1 Palestinian). 4 To date, 24 affected individuals have been reported worldwide, with an estimated prevalence of less than 1 in 1,000,000. 5 Subsequent cases have been described in several other ethnic backgrounds, including Irish, Italian, Czech, Palestinian, and Pakistani populations. As demonstrated across reported cases, diagnosis has involved a combination of characteristic clinical features, brain magnetic resonance imaging findings, and molecular confirmation of pathogenic variants in SLC1A4, most commonly identified using whole-exome sequencing.1,4 Therapeutic approaches using L-serine supplementation have been attempted in disorders of serine biosynthesis; however, the benefit of serine supplementation in serine transport defects remains uncertain, as the major neurological abnormalities are thought to arise during early intrauterine development. 2 Severe neurological impairment in classical serine deficiency disorders can only be effectively prevented through prenatal or very early postnatal administration of L-serine, a limitation that should be considered when evaluating serine replacement therapy in SPATCCM. 6 Here, we report a child with a pathogenic variant in SLC1A4 who demonstrates clinical features that partially overlap with previously reported cases, while also exhibiting novel manifestations that further expand the phenotypic spectrum of this ultra-rare disorder.

Case Presentation

The patient is a 30-month-old male, born at 39 weeks of gestation to consanguineous parents (first cousins), with a birth weight of 1950 grams and a head circumference (HC) of 28 cm. He presented to our clinic with a history of progressive microcephaly, spastic tetraplegia, recurrent infections, and dysphagia, all of which were evident since early infancy. His motor development has been significantly delayed, as he was unable to sit independently or roll over by 8 months of age. While he showed weight-bearing in his lower extremities, he lacked purposeful upper extremity reach. Social and communication development was also delayed, though he maintained preserved eye contact.

His medical and surgical history includes the repair of bilateral inguinal and umbilical hernias at 2 months of age and a meatal stenosis repair at 9 months. Seizures began at 4 months of age and were managed with sodium valproate, with carbamazepine added at 26 months of age, while baclofen was used for spasticity control. Despite these interventions, he has experienced frequent recurrent infections (approximately every 10 days) since birth. His feeding difficulties, noted since birth, were further evaluated with a video fluoroscopy swallowing study, which revealed impaired bolus control and inadequate management of textured food, especially thicker consistencies. Due to his compromised oral musculature, a G-tube placement was recommended for long-term nutritional support.

On physical examination, performed at 30 months of age, the patient’s HC measured 38 cm, indicating continued microcephaly. His growth parameters included a weight of 7 kg and a length of 73 cm. Head circumference-for-age demonstrated severe progressive microcephaly, with values consistently below the 3rd percentile (Z-score ≈ −7.8 at 30 months). Weight-for-age and length-for-age were markedly below the expected range throughout follow-up, corresponding to severe weight-for-growth restriction (Z-score ≈ −4.7) and severe length-for-age growth restriction (Z-score ≈ −5.3) at 30 months of age. Craniofacial assessment was significant for microcephaly, retrognathia, and a high-arched palate (Figure 1A and B). The ears were noted to be low-set and posteriorly rotated with a prominent antihelix (Figure 1C).

Figure 1.

Figure 1.

Clinical photographs of the patient at 30 months.

(A and B) Lateral and frontal views demonstrating microcephaly, retrognathia, and clinical signs of failure to thrive with visible rib prominence. Axial hypotonia and limb posturing consistent with spastic tetraplegia were observed on neurological examination. (C) Close-up of the auricular region showing low-set, posteriorly rotated ears with a prominent antihelix. (D) Close-up of the hand demonstrating grade 2 digital clubbing, characterized by softening of the nail bed and loss of the Lovibond angle.

Note. The thoracic profile in panel (A) demonstrates pectus carinatum

The patient’s nutritional status was consistent with failure to thrive, evidenced by a lack of subcutaneous fat and visible rib prominence. Thoracic examination revealed a distinct pectus carinatum (Figure 1A). Neurologically, the patient demonstrated a combination of axial hypotonia and limb spasticity consistent with spastic tetraplegia and global developmental delay. Examination of the extremities revealed grade 2 digital clubbing, characterized by the softening of the nail beds and loss of the Lovibond angle (Figure 1D). Brain imaging, including MRI performed at 7 months of age, was negative for acute infarct, hemorrhage, or ventriculomegaly. However, imaging revealed a diffusely thin corpus callosum despite the presence of all anatomical segments (rostrum, genu, body, and splenium), suggesting a primary structural hypoplasia rather than an acquired injury (Figure 2). An auditory examination revealed normal tympanometry, DPOAE, and ABR responses, indicating no hearing loss.

Figure 2.

Figure 2.

Neuroimaging at 7 months of age.

(A) Coronal T1-weighted image showing symmetric supratentorial brain development for a 7-month-old infant, without ventriculomegaly or significant cortical volume loss. (B) Mid-sagittal T2-weighted sequence demonstrating a diffusely thin corpus callosum. While the rostrum, genu, body, and splenium are present, they lack the expected age-appropriate thickness and bulbous morphology. The brainstem and cerebellar vermis appear preserved. No gross abnormalities of myelination are apparent on the sequences shown for this developmental stage, though structural thinning of the commissural fibers is evident

The patient was diagnosed with spastic tetraplegia and progressive microcephaly, which was later confirmed through whole-exome sequencing. Genetic testing identified a homozygous pathogenic variant in SLC1A4 (NM_003038.5:c.1369C>T, p.Arg457Trp), diagnosing him with an autosomal recessive neurodevelopmental disorder known as SPATCCM. His family history is notable for the consanguinity of his parents. The parents are clinically unaffected; however, parental genotyping was not available. Given the autosomal recessive inheritance pattern of SLC1A4-related SPATCCM and the consanguinity of the parents, heterozygous carrier status is strongly inferred.

The patient’s older sibling, a 3-year-old female, demonstrated normal head circumference (48 cm, 50th percentile) and age-appropriate developmental milestones. Subsequent testing confirmed she is heterozygous for the SLC1A4 (NM_003038.5:c.1369C>T; p.Arg457Trp) pathogenic variant, consistent with carrier status. Genetic counseling was provided to the family regarding autosomal recessive inheritance and future reproductive options. Whole-exome sequencing (WES) was performed at Hadassah Hospital (Jerusalem) using the Illumina NovaSeq platform (average coverage >100×; 98% ≥20×). Bioinformatic analysis followed ACMG 2021 guidelines.

WES identified a homozygous SLC1A4 variant (NM_003038.5:c.1369C>T; p.Arg457Trp). This variant is classified as pathogenic according to ACMG criteria and is annotated as pathogenic/likely pathogenic in ClinVar. It has been previously reported in individuals with spastic tetraplegia, thin corpus callosum, and progressive microcephaly. The variant occurs at a very low allele frequency in population databases (∼0.00012), with no healthy homozygotes reported, further supporting its pathogenicity in autosomal recessive SLC1A4-related disease.

No chromosomal microarray or additional genetic testing was performed. Whole-exome sequencing does not capture noncoding regions, genes with high homology to pseudogenes, or repeat expansions such as Fragile X. CNV and SV analysis did not reveal any relevant findings. Therefore, although technical limitations prevent the absolute exclusion of all possible genetic contributors, no evidence of an alternate primary or secondary diagnosis was identified.

Discussion

SLC1A4 was identified as a disease-causing gene in 2015 by Srour et al, 3 who described biallelic mutations in an Ashkenazi Jewish family, and Damseh et al, 4 who described biallelic mutations in Ashkenazi Jewish and Palestinian families, naming the condition SPATCCM. Later studies reported novel pathogenic variants in patients from Pakistani, 2 Portuguese, 7 and Turkish populations. 5

SLC1A4-related disorders result from biallelic pathogenic variants in the SLC1A4 gene, which encodes the ASCT1 serine transporter.4,8 Parental consanguinity has been reported in families with SLC1A4-related disorder, consistent with its autosomal recessive inheritance pattern.3,4 Phenotypic severity correlates with mutation type in SLC1A4, with combined loss-of-function and missense variants resulting in more severe disease than missense variants alone. 8 In serine biosynthesis defects, a clinical spectrum ranging from severe infantile to milder juvenile phenotypes has been described, though biochemical findings cannot reliably predict clinical severity.9,10 Serine supplementation as a therapeutic approach in SLC1A4 disorder remains hypothetical. 8

SLC1A4 pathogenic variants impair the ASCT1 transporter, reducing L-serine uptake in the brain.4,8,11 L-serine is essential for neuronal proliferation, migration, myelination, and synthesis of phospholipids and D-serine, the latter being a co-agonist of NMDA receptors.10,12 Deficiency of L-serine disrupts these processes, contributing to the neurological features of SPATCCM.

SLC1A4-related disorders present with three defining neurological features: (1) progressive microcephaly beginning in infancy, (2) spastic tetraplegia with hypertonia, and (3) a thin corpus callosum, often with hypomyelination visible on brain imaging.3,4,8 Affected individuals commonly show global developmental delay and intellectual disability ranging from moderate to severe.3,4,8 Seizures are a recognized feature of SLC1A4-related disorder, with manifestations ranging from simple febrile seizures to intractable epilepsy.3,4,8,13 Additional features include feeding difficulties, growth retardation, and occasionally stereotypic hand movements.4,8,9

In our case, the patient exhibited the classic phenotype of SPATCCM, including progressive microcephaly, severe global developmental delay, spastic tetraplegia, and seizures. Dysphagia was confirmed by videofluoroscopy, and persistent low weight and length were noted. A significant communication delay was observed, as the patient produced only babbling without meaningful speech, while auditory examination excluded hearing impairment. Notably, his older sister was found to be heterozygous for the same variant and demonstrated normal development, consistent with carrier status. However, objective clinical examination, neuroimaging, and formal neurodevelopmental testing were not available.

Furthermore, our patient exhibited several previously unreported or rare findings: (1) grade 2 finger clubbing, which was unreported in the 24 cases reviewed by Yalçın et al 5 ; (2) recurrent infections since birth, potentially due to aspiration secondary to bulbar dysfunction 4 or a previously unrecognized immune component of serine deficiency 14 ; (3) bilateral inguinal and umbilical hernias requiring repair at 2 months, a feature occasionally reported in serine deficiency disorders 9 ; (4) meatal stenosis (repaired at 9 months), representing, to our knowledge, the first documented genitourinary anomaly in SPATCCM; and (5) a divergent dysmorphic profile, including high-arched palate, low-set ears, and pectus carinatum, contrasting with the more common brachycephaly and midface retrusion. 5 While these novel multisystem features are not currently explained by SLC1A4, no alternative molecular cause was identified in the available testing. Thus, although technical limitations prevent absolute exclusion of other genetic contributors, the data support SLC1A4 as the primary molecular diagnosis and highlight previously unreported multisystem manifestations. (Table 1).

Table 1.

Comparison of Phenotypic Findings and SLC1A4 Variants Across Reported Cases

Comparison of Clinical Features in SLC1A4-Related SPATCCM: Current Case vs. Literature
Clinical Feature Current Case Damseh et al (2015) Srour et al (2015) Heimer et al (2015) Abdelrahman et al (2019) Teixeira et al (2020) Sarigecili et al (2022) Yalçın et al (2024) Frequency in Literature
Gene Variant p.Arg457Trp (homozygous) p.E256K (homozygous) p.E256K/p.L315fs (Compound heterozygous) p.R457W (homozygous) p.E256K/wt (heterozygous, unaffected) p.E256K (homozygous) c.766G>A/c.945delTT (compound heterozygous) c.766G>A (homozygous) p.Y191* (homozygous) c.272T>C, p.(Leu91Pro) (homozygous) c.527+1G>T/c.1035-1G>T (Compound heterozygous) p.Gly374Arg (homozygous) p.R457W (homozygous) Multiple pathogenic variants (p.E256K homozygous most common)
Progressive Microcephaly ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Universal feature
Spastic Tetraplegia ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Universal feature (may begin as hypotonia evolving to spasticity)
Thin Corpus Callosum ✓ ✓ (4/10) ✓ ✓ ✓ (Patient 1) ✓ (Patient 1 only) ✓ ✓ Hallmark of the condition, but they are not universally present
Patient 2 MRI not available
Seizures ✓ Variable (5/11) ✓ febrile(1/2) ✓ Patient 1 (tonic, non-febrile) ✓ ✓ (Patient 2 only) ✓ ✗ Reported in ∼52% of cases ranges from febrile seizures to intractable epilepsy
✓Patient 2 (febrile)
Feeding Difficulties ✓ (G-tube placed) NR NR ✓ (Patient 1 only) ✓ Patient 1 (aspiration pneumonia, chewing/swallowing difficulties, drooling) NR ✗ NR underreported given severity of neurological involvement
Patient 2 (NR)
Dysmorphic Features ✓ (high-arched palate, low-set ears, pectus carinatum) ✗ ✗ ✗ ✓ (hypertelorism, depressed nasal bridge, synophrys, and prominent ears) ✓ (Patient 1 only) hypertelorism, broad flat philtrum, large mouth, thin upper lip, everted lower lip facial dysmorphis ✓ (Brachycephaly,Plump cheeks, Deep-set eyes, Midface retrusion, Flat nose root,High palate,Short neck, Pectus carinatum) present in ∼40-50% of cases; no consistent dysmorphic pattern across all patients
Recurrent Infections ✓ (∼every 10 days since birth) NR NR NR NR NR NR NR Rarely reported as a systemic pattern
Digital Clubbing ✓ (Grade 2) NR NR NR NR NR NR NR Novel
Genitourinary Anomalies ✓ (meatal stenosis) NR NR NR NR NR NR NR Novel
Hernias ✓ (bilateral inguinal & umbilical) NR NR NR NR NR NR NR Novel in SPATCCM; occasionally reported in serine biosynthesis disorders (not previously documented in SLC1A4-related disease)

✓ Present, ✗ Absent, NR = Not Reported.

Notes. NR = Not Reported. Frequency estimates are based on all published SLC1A4 cases as of 2024. Recurrent infections, Digital clubbing, genitourinary anomalies, and hernias represent novel features first documented in the current case.

The diagnosis of SPATCCM is suspected based on a combination of characteristic clinical features and confirmed by genetic testing.1,4 Key diagnostic criteria include early infantile onset of severe neurodevelopmental delay, progressive microcephaly, and spastic tetraplegia.2,4 Brain imaging findings such as thin corpus callosum, hypomyelination, and white matter abnormalities are frequently observed and considered a hallmark of the condition, but they are not universally present.1,2,4 In our patient, neuroimaging at 7 months of age demonstrated a diffusely thin corpus callosum, consistent with the classic SPATCCM phenotype. Mid-sagittal T2-weighted sequences confirmed that while the rostrum, genu, body, and splenium are present, they lack the expected age-appropriate thickness and bulbous morphology.

Notably, other imaging abnormalities often associated with this condition were absent; coronal T1-weighted images showed normal symmetric brain development with no evidence of ventriculomegaly, cortical volume loss, or gross delays in myelination. The preservation of the brainstem and cerebellar vermis further highlights the variability in structural brain changes, suggesting that white matter abnormalities may be a downstream or non-universal consequence of the underlying serine transport defect. These findings underscore the importance of proceeding to genetic testing for a definitive diagnosis, even when global brain structure appears otherwise unremarkable.

Management is primarily supportive, with an emphasis on seizure control. 15 Serine supplementation has been proposed as a potential targeted therapy, given the overlapping features with L-serine biosynthesis disorders in which supplementation appeared beneficial; however, its efficacy in SLC1A4 deficiency has not been established.4,15 In our patient, seizures began at 4 months of age and were managed with sodium valproate, with carbamazepine added at 26 months of age, while baclofen was used for spasticity control.

Conclusion

This case expands the phenotypic spectrum of SLC1A4-related SPATCCM by documenting previously unreported or rarely described multisystem manifestations, including genitourinary anomalies, recurrent infections, and digital clubbing. Neuroimaging demonstrated a diffusely thin corpus callosum, a hallmark feature of SPATCCM, in the absence of additional major structural brain abnormalities. These findings highlight the clinical variability of SLC1A4-related disorders and underscore the importance of molecular genetic testing for definitive diagnosis, even when neuroimaging does not demonstrate extensive white matter involvement. Recognition of such phenotypic variability enhances clinical awareness, supports accurate genetic counseling, and may inform future therapeutic considerations, including early targeted metabolic interventions, whose efficacy in this disorder remains to be established.

Acknowledgements

The authors express their gratitude to the patient and their family for their great contribution. Also the authors express profound gratitude to the Polytechnic Medical Students’ Research Association (PMRA) for their invaluable contributions and unwavering support that significantly enriched every stage of the research journey.

Footnotes

Funding: The authors received no financial support for the research, authorship, and/or publication of this article.

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

ORCID iDs

Leyana Alawawdeh https://orcid.org/0009-0002-7302-7661

Baraa Nassar https://orcid.org/0009-0002-3219-7648

Taha Z. Makhlouf https://orcid.org/0009-0009-9578-1105

Ethical Considerations

Our institution does not require ethical approval for reporting individual cases or case series.

Consent for Publication

Written informed consent was obtained from the patient’s family for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal if requested.

Data Availability Statement

The data used to support the findings of this study are included in the article.*

References

  • 1.Mohamed FE, Ghattas MA, Almansoori TM, et al. Novel compound heterozygous variants (c.971delA/c.542C>T) in SLC1A4 causes spastic tetraplegia, thin corpus callosum, and progressive microcephaly: a case report and mutational analysis. Front Pediatr. 2023;11:1183574. doi: 10.3389/fped.2023.1183574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Abdelrahman HA, Al-Shamsi A, John A, Ali BR, Al-Gazali L. A novel SLC1A4 mutation (p.Y191*) causes spastic tetraplegia, thin corpus callosum, and progressive microcephaly (SPATCCM) with seizure disorder. Child Neurol Open. 2019;6:2329048X19880647. doi: 10.1177/2329048X19880647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Srour M, Hamdan FF, Gan-Or Z, et al. A homozygous mutation in SLC1A4 in siblings with severe intellectual disability and microcephaly. Clin Genet. 2015;88:e1-e4. doi: 10.1111/cge.12605. [DOI] [PubMed] [Google Scholar]
  • 4.Damseh N, Simonin A, Jalas C, et al. Mutations in SLC1A4, encoding the brain serine transporter, are associated with developmental delay, microcephaly and hypomyelination. J Med Genet. 2015;52:541-547. doi: 10.1136/jmedgenet-2015-103104. [DOI] [PubMed] [Google Scholar]
  • 5.Yalçın HY, Cinleti T, Yeşilyurt A, Aydın N. Report of a new pediatric patient with the SLC1A4 variant and a brief review of the literature. J Pediatr Neurol. 2024;22:301-306. doi: 10.1055/s-0044-1778705. [DOI] [Google Scholar]
  • 6.Odeh M, Sajrawi C, Majcher A, et al. A new type of blood-brain barrier aminoacidopathy underlies metabolic microcephaly associated with SLC1A4 mutations. Brain. 2024;147:3874-3889. doi: 10.1093/brain/awae134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Teixeira J, Dória S, Santos M, et al. Progressive microcephaly, spasticity and developmental delay: novel SLC1A4 variants in two Portuguese families and literature review. J Genet Genomic Sci. 2020;5:017. doi: 10.24966/GGS-2485/100017. [DOI] [Google Scholar]
  • 8.Heimer G, Marek-Yagel D, Eyal E, et al. SLC1A4 mutations cause a novel disorder of intellectual disability, progressive microcephaly, spasticity and thin corpus callosum. Clin Genet. 2015;88:327-335. doi: 10.1111/cge.12637. [DOI] [PubMed] [Google Scholar]
  • 9.Van der Crabben SN, Verhoeven-Duif NM, Brilstra EH, et al. An update on serine deficiency disorders. J Inherit Metab Dis. 2013;36:613-619. doi: 10.1007/s10545-013-9592-4. [DOI] [PubMed] [Google Scholar]
  • 10.Tabatabaie L, Klomp LW, Berger R, de Koning TJ. L-serine synthesis in the central nervous system: a review on serine deficiency disorders. Mol Genet Metab. 2010;99:256-262. doi: 10.1016/j.ymgme.2009.10.012. [DOI] [PubMed] [Google Scholar]
  • 11.El-Hattab AW. Serine biosynthesis and transport defects. Mol Genet Metab. 2016;118:153-159. doi: 10.1016/j.ymgme.2016.04.010. [DOI] [PubMed] [Google Scholar]
  • 12.Glinton KE, Benke PJ, Lines MA, et al. Disturbed phospholipid metabolism in serine biosynthesis defects revealed by metabolomic profiling. Mol Genet Metab. 2018;123:309-316. doi: 10.1016/j.ymgme.2017.12.009. [DOI] [PubMed] [Google Scholar]
  • 13.Sarigecili E, Bulut FD, Anlas O. A rare cause of microcephaly, thin corpus callosum and refractory epilepsy due to a novel SLC1A4 gene mutation. Clin Neurol Neurosurg. 2022;218:107283. doi: 10.1016/j.clineuro.2022.107283. [DOI] [PubMed] [Google Scholar]
  • 14.Ma EH, Bantug G, Griss T, et al. Serine is an essential metabolite for effector T cell expansion. Cell Metab. 2017;25:345-357. doi: 10.1016/j.cmet.2016.12.011. [DOI] [PubMed] [Google Scholar]
  • 15.Pironti E, Salpietro V, Cucinotta F, et al. A novel SLC1A4 homozygous mutation causing congenital microcephaly, epileptic encephalopathy and spastic tetraparesis: a video-EEG and tractography case study. J Neurogenet. 2018;32:316-321. doi: 10.1080/01677063.2018.1476510. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data used to support the findings of this study are included in the article.*


Articles from Journal of Investigative Medicine High Impact Case Reports are provided here courtesy of SAGE Publications

RESOURCES